Generic Name and Formulations:
Doxepin HCl 5%; crm.
Indications for ZONALON:
Moderate pruritus associated with atopic dermatitis and lichen simplex chronicus.
Apply thin film to affected area 4 times a day at 3–4 hour intervals for up to 8 days. Do not occlude.
Untreated narrow-angle glaucoma. Urinary retention.
During or within 14 days of MAOIs. Poor metabolizers may have increased effects. For dermatological use only. Avoid eyes. Pregnancy (Cat.B). Nursing mothers: not recommended.
Discontinue MAOIs at least 2 weeks before starting. Alcohol, CNS depressants potentiate sedation. May potentiate drugs metabolized by CYP2D6 (eg, cimetidine, tricyclic antidepressants, SSRIs, phenothiazines, carbamazepine, propafenone, flecainide, encainide, quinidine).
Drowsiness, dry mouth, thirst, headache, fatigue, dizziness, emotional or taste changes, burning/stinging, pruritus or eczema exacerbation, skin dryness or tightening, parethesias, edema.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma
- Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|